<DOC>
	<DOC>NCT02906124</DOC>
	<brief_summary>To evaluate outcomes of pregnancy in females diagnosed with familial hypercholesterolaemia (FH), exposed to Repatha® during pregnancy. This includes follow-up of their infants to the age of 12 months</brief_summary>
	<brief_title>Study to Evaluate the Safety of Repatha® in Pregnancy</brief_title>
	<detailed_description>Women diagnosed with familial hypercholesterolaemia (FH), treated at centres in Europe, South Africa and Australia, with pregnancy confirmed during the study observation period and who provide informed consent to participate in the study. Exposed subjects are women who received Repatha® during pregnancy and/or breastfeeding; unexposed subjects are women who have not received Repatha® during pregnancy and/or breast-feeding. In infants, exposure may occur in utero and/or via breast milk, within 15 weeks following the date of Repatha® dosing in the mother</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Females diagnosed with Familial hypercholesterolaemia (FH). Confirmed pregnancy during the study observation period. Provided informed consent to followup in this study, for subject and their infant(s) born during the study observation period There are no exclusion criteria</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hypercholesterolaemia</keyword>
	<keyword>Lipid lowering therapies</keyword>
	<keyword>Pregnancy</keyword>
</DOC>